Pfizer apply to the EU marketing authorization of the anti-cancer drug Axitinib
It is reported that Pfizer said it has submitted a marketing authorization application of drug candidates for the treatment of advanced renal cell carcinoma axitinib. Renal cell carcinoma is the most common form of kidney cancer.
The company is based on the findings is seeking Food and Drug Administration approval. The results of these studies show that, compared with patients given Nexavar treatment given axitinib treatment patients can survive longer without disease progression. Nexavar is an anti-cancer drug was approved in December 2005.
June 1, Pfizer requests the EU regulatory approval of axitinib as other treatments ineffective treatment of advanced renal cell carcinoma patients.
The New York drugmaker said, there are around 21 people are diagnosed with kidney cancer, there are about 102,000 patients die from the disease. It said that about 20% of patients can survive for five years or more.
Nexavar by Onyx Pharmaceuticals and Bayer HealthCare sales. The drug is also approved for the treatment of liver cancer
Pfizer apply to the EU marketing authorization of the anti-cancer drug Axitinib
ReplyDeleteIt is reported that Pfizer said it has submitted a marketing authorization application of drug candidates for the treatment of advanced renal cell carcinoma axitinib. Renal cell carcinoma is the most common form of kidney cancer.
The company is based on the findings is seeking Food and Drug Administration approval. The results of these studies show that, compared with patients given Nexavar treatment given axitinib treatment patients can survive longer without disease progression. Nexavar is an anti-cancer drug was approved in December 2005.
June 1, Pfizer requests the EU regulatory approval of axitinib as other treatments ineffective treatment of advanced renal cell carcinoma patients.
The New York drugmaker said, there are around 21 people are diagnosed with kidney cancer, there are about 102,000 patients die from the disease. It said that about 20% of patients can survive for five years or more.
Nexavar by Onyx Pharmaceuticals and Bayer HealthCare sales. The drug is also approved for the treatment of liver cancer
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
GSK1904529A
Linsitinib
NVP-ADW742
BMS-536924
GSK1904529A
NVP-AEW541
Linsitinib
Pazopanib
Crenolanib
Toceranib